Survey Supports Puma Biotechnology (PBYI) Nerlynx Bull Case - Citi; PT Lowered to $151
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Guggenheim Starts Puma Biotechnology (PBYI) at Buy
September 17, 2018 4:33 PM EDTGuggenheim analyst Michael Schmidt initiates coverage on Puma Biotechnology (NASDAQ: PBYI) with a Buy rating and a price target of $85.00.
For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.
Shares of Puma Biotechnology closed at $47.00 yesterday.
... MorePre-Open Movers 09/17: (SNMX) (NBEV) (SIR) Higher; (RSLS) (PBYI) (TWTR) Lower (more...)
September 17, 2018 9:28 AM EDTToday's Pre-Open Stock Movers
Senomyx, Inc. (NASDAQ: SNMX) 41% HIGHER; Firmenich and Senomyx, Inc. (NASDAQ: SNMX) today announced that they have entered into a definitive merger agreement under which Firmenich will acquire all of the outstanding common stock of Senomyx for $1.50 per share in cash. This represents a premium of approximately 43% over Senomyx's closing price on September 14, 2018 and a premium of approximately 39% based on the prior 30-trading day volume-weighted average price (VWAP). The proposed transaction has been unanimously approved by the Boards... More
Goldman Sachs Starts Puma Biotechnology (PBYI) at Sell
September 17, 2018 5:17 AM EDTGoldman Sachs analyst Paul Choi initiates coverage on Puma Biotechnology (NASDAQ: PBYI) with a Sell rating and a price target of $42.00.
The analyst initiates SMID Biotech sector at Neutral. He is negative on PBYI noting it is primarily trading on patient growth... More
